EGFR and non-small cell lung carcinoma: Cisplatin-based chemotherapy remains the first-line drug for NSCLC patients without epidermal growth factor receptor (EGFR) mutations; however, drug resistance can develop during therapy through varied mechanisms, such as mediation by activation of the IL-6/signal transducer.